Caricamento...
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
BACKGROUND: Because the general population is largely naive to H5N1 influenza, antibodies generated to H5 allow analysis of novel influenza vaccines independent of background immunity from previous infection. We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improv...
Salvato in:
| Pubblicato in: | Lancet Infect Dis |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier Ltd.
2011
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7185472/ https://ncbi.nlm.nih.gov/pubmed/21975270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(11)70240-7 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|